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Background: Praziquantel (PZQ) is the mainstay of schistosomiasis control and has been successfully used for
decades. However, its mechanism of action is not fully understood. While the majority of studies have been
conducted on Schistosoma mansoni, it is not known which enantiomer, R- or S-praziquantel (R-/S-PZQ), is
responsible for the activity on Schistosoma haematobium.
Methods: In vitro and in vivo studies were conducted to evaluate the activity of R- and S-PZQ, racemic PZQ and
the main human metabolite, namely trans-4-OH-PZQ, on S. haematobium. IC50 values on adult S. haematobium
were determined in vitro. Dose-response relationship studies were performed in golden Syrian hamsters,
harbouring a chronic S. haematobium infection.
Results: R-PZQ displayed the highest activity against adult worms in vitro, revealing an IC50 of 0.007 μg/ml at 4 h
and 0.01 μg/ml at 72 h. In contrast, S-PZQ was 501× less active (eudysmic ratio at 4 h), with an IC50 of 3.51 and
3.40 μg/ml (4 and 72 h, respectively). Racemic PZQ and trans-4-OH-PZQ resulted in an IC50 of 0.03 μg/ml and
1.47 μg/ml both at 4 and 72 h, respectively. In vivo, R-PZQ was the most potent drug with worm burden
reductions (WBRs) of 98.5, 75.6 and 73.3% at 125.0, 62.5 and 31.0 mg/kg, respectively. A single oral dose of
250.0 mg/kg PZQ resulted in a WBR of 99.3%. S-PZQ was highly active in vivo at 250.0 and 500.0 mg/kg with WBRs
of 83.0 and 94.1%, respectively. The lowest tested dose of S-PZQ, 125.0 mg/kg, showed moderate activity (WBR of
46.7%). The calculated ED50 for
R- and S-PZQ were 24.7 and 127.6 mg/kg, respectively, with a corresponding eudysmic ratio of 5.17.
Conclusion: Our data support the theory of R-PZQ driving the antischistosomal activity. Interestingly, also S-PZQ
proved to possess a significant activity towards S. haematobium, particularly in vivo.
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Schistosomiasis is one of the prominent neglected trop-
ical diseases (NTDs), caused by blood-dwelling flukes of
the genus Schistosoma. It is affecting over 230 millions
of people around the world, mostly concentrated in
poor, tropical and subtropical areas [1–3].
Intestinal schistosomiasis, caused by S. mansoni and
S. japonicum, manifests with abdominal symptoms (e.g.
blood in stool, abdominal discomfort, diarrhoea) and can
lead to liver failure [4, 5], while S. haematobium causes urin-
ary schistosomiasis, triggering bladder pathology, often
resulting in bladder cancer [4, 6]. In addition, schistosomiasis
influences the course and outcome of pregnancy and affects
child’s intellectual and physiological development [7, 8].
Praziquantel (PZQ) is the only effective drug available
against schistosomiasis and has been successfully in use
for decades [4, 6, 9–13]. Originating from veterinary
medicine and repurposed for human use, it has been
thoroughly studied; however, knowledge regarding the
mechanism of action is scarce [9, 11]. PZQ is a racemic
compound consisting of two enantiomers, R- and S-
PZQ [9, 11]. While there have been some in vitro and
in vivo studies on the activity of PZQ, they mostly stu-
died the racemic drug [14–20]. In the few studies, which
explored the activity of either R- or S-PZQ, the reported
findings vary. Nevertheless, most studies reported
greater activity of R-PZQ over S-PZQ [21–24]. Staudt
et al. [24] suggested that the main metabolite, R-trans-4-
hydroxy-praziquantel (trans-4-OH-PZQ), also possesses
a high antischistosomal activity on S. mansoni. A similar
finding was reported by Xiao et al. [25] for S. japonicum.
It is worth highlighting that the above-mentioned stu-
dies, testing the enantiomeric activity of R- and S-PZQ,
were conducted using exclusively S. mansoni and S. japo-
nicum. Schistosoma haematobium remains largely unex-
plored, regardless of the fact that it is responsible for the
largest number of infections [26]. One of the many rea-
sons of negligence might be the life-cycle of the parasite,
which is difficult to maintain in laboratory conditions
[27–29]. However, drug activity should be carefully eluci-
dated on S. haematobium as well, since there is evidence
that the activity of drugs, e.g. PZQ, oxamniquine or metri-
fonate, differs between species of the parasite [18, 30].
In this study, the activity of both PZQ enantiomers, R-
and S-PZQ, as well as the racemic drug and the main
metabolite (trans-4-OH-PZQ) was assessed on S. hae-
matobium. The activity of all entities was tested in vitro
on adult worms and the results were reported as IC50
values. The S. haematobium hamster model was used
for testing different dosages of R-PZQ and S-PZQ
compared with racemic PZQ in vivo. ED50 values were
reported and worm burden reductions (WBRs) were
compared between different treatment groups of R- and
S-PZQ and the control group.Methods
Drugs, media and animals
Pure analytes, R-, S- and trans-4-OH-PZQ were kindly
supplied by Merck (Darmstadt, Germany). Racemic PZQ
was purchased from Sigma Aldrich (Buchs, Switzerland).
Drugs for in vitro studies were dissolved in dimethyl
sulfoxide (DMSO; Fluka, Buchs, Switzerland). A mixture
of 7% (vol/vol) Tween 80 and 3% ethanol (vol/vol) was
used to suspend the drugs for in vivo treatment.
For cultivating adult schistosomes, standard RPMI
1640 medium (Life Technologies, Carlsbad, CA, USA)
with addition of 5% heat-inactivated foetal calf serum
(iFCS), 100 U/ml of penicillin (Life Technologies) and
100 μg/ml of streptomycin (Life Technologies) was used.
Thirty LVG golden Syrian hamsters (male, weight ap-
proximately 150 g), infected with approximately 350 cer-
cariae of S. haematobium each, were obtained from the
biomedical research institute (NR-21966, Rockville, MD,
USA). The animals were kept under controlled condi-
tions (22 °C, 50% humidity, 12/24 h of light and free ac-
cess to water and rodent diet) to allow development of
chronic infection 3 months post-exposure.
In vitro and in vivo studies
In vitro studies
Adult worms were tested at a range of 0.01–3.00 μg/ml
for R-PZQ and PZQ, at 0.1–30.0 μg/ml for S-PZQ and
0.1–3.0 μg/ml for trans-4-OH-PZQ. Drugs were pre-
pared in medium using serial dilutions in flat bottom
24-well plates (BD, Falcon, Corning, NY, USA). Control
wells consisted of 0.3% DMSO, which was the highest
concentration of DMSO used to dissolve the drugs.
Three months post-infection, S. haematobium-infected
hamsters were euthanized with CO2 and dissected. Adult
worms were collected from hepatic portal and mesen-
teric veins. Two to three worms, sexes equally repre-
sented, were placed per well and each concentration of
the drug was tested in duplicates. Worms were incu-
bated at 37 °C and 5% CO2 and the phenotypic changes
were evaluated 1, 4, 24, 48 and 72 h post-incubation
using a motility scale ranging from 3 (normal activity) to
0 (no activity, granularity present).
IC50 values were calculated with CompuSyn® software
(version 1.0) from motility values at different concentra-
tions of each drug. The linear correlation coefficient (r
value) reflects the conformity of the experimental data.
The eudysmic ratio was calculated using the following
formula: IC50 distomer/IC50 eutomer, where R-PZQ is
the eutomer and S-PZQ the distomer.
In vivo studies
Infected S. haematobium hamsters in groups of 3–4 were
treated 3 months post-infection with a single oral dose of
250.0 mg/kg PZQ, 125.0 mg/kg R-PZQ, 62.5 mg/kg
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250.0 mg/kg S-PZQ or 125.0 mg/kg S-PZQ. 10 days post-
treatment hamsters were euthanized with CO2 and dis-
sected. Adult worms from intestinal veins were counted
and sexed and the liver was inspected for live/dead worms
and eggs. The control group (untreated) was dissected at
the same time and the mean worm burden of treated
hamsters was compared with untreated hamsters to
determine the WBR. ED50 and eudysmic ratios were
calculated as described above.
Statistics
Statistical tests were performed using Prism software
(version 7.03, GraphPad, CA, USA). Unpaired t-test allow-
ing for unequal variances was used to determine differences
in worm burden between the control group and the treat-
ment groups. P < 0.05 was considered to be significant.
Results
In vitro studies
In vitro IC50 and IC90 values (4 and 72 h of incubation)
of racemic PZQ, pure enantiomers and trans-4-OH-
PZQ obtained against adult worms of S. haematobium
are summarised in Table 1. The IC50 of R-PZQ was
0.007 μg/ml at 4 h and 0.01 μg/ml at 72 h, while S-PZQ
was 501× less active (eudysmic ratio at 4 h) yielding IC50
values of 3.51 and 3.40 μg/ml (4 and 72 h, respectively).
The IC50 of PZQ was 0.03 μg/ml, which is 4.3× higher
compared to R-PZQ. Trans-4-OH-PZQ revealed an IC50
of 1.47 μg/ml at 4 and 72 h, respectively.
In vivo studies
Total WBRs and female WBRs following different single
oral doses of R-, S-PZQ and PZQ are presented in Table 2.
For all drugs and dosages tested, a higher activity on the fe-
male worms was observed. PZQ reduced the total worm
burden by 99.3% at a single dose of 250.0 mg/kg. R-PZQ
showed the highest total WBR at 125.0 mg/kg (98.5%)
while with a half of the dose (62.5 mg/kg) the WBR was
lower (75.6%). The lowest dose of R-PZQ, 31.0 mg/kg,
yielded still a high total WBR of 73.3%. S-PZQ revealed a
high activity at 500.0 and 250.0 mg/kg with total WBRs of
94.1 and 83.0%. A moderate total WBR of 46.7% was ob-
served when the hamsters were treated with 125.0 mg/kg
of S-PZQ. The calculated ED50s for R- and S-PZQ
were 24.7 and 127.6 mg/kg, respectively, with aTable 1 IC50 and IC90 values of PZQ, R-PZQ, S-PZQ enantiomers and
IC50 at 4 h (μg/ml) r-value IC50 at 72 h (μg/m
PZQ 0.03 0.978 0.03
R-PZQ 0.007 0.803 0.01
S-PZQ 3.51 0.925 3.40
Trans-4-OH-PZQ 1.47 0.891 1.47corresponding eudysmic ratio of 5.17. All female and
total WBRs of the different treatment groups were signifi-
cantly different from the control group (P < 0.05),
except for the total WBRs of lowest doses of R- and
S-PZQ (31.0 mg/kg and 125.0 mg/kg, respectively),
which showed not to be significantly better compared
to the control group.
Discussion
With no available alternative drug, PZQ is the mainstay
of schistosomiasis control [9–12]. Apart from reliance
on a single drug, an additional drawback is the large
dose required, resulting in a huge size of the tablet, con-
taining a racemic mixture of PZQ [31–33]. The discus-
sion about the activity of each enantiomer of the drug,
namely R- and S-PZQ, has been on-going and therefore
it is time to conclude which enantiomer is responsible
for the antischistosomal activity [9, 32–34]. Moreover,
development of a paediatric PZQ formulation is cur-
rently ongoing and thorough examination of in vitro
and in vivo activity of PZQ and its enantiomers will not
only contribute to a better understanding of the drug
but also aid to select the optimal entity for the final for-
mulation (R-PZQ or racemic PZQ) [35]. While S. mansoni
has been thoroughly researched, S. haematobium remains
neglected in the laboratory, despite of being responsible
for a large share of the burden of schistosomiasis [26, 29].
This holds true also for drug sensitivity testing including
studies on PZQ. While a few studies assesed the activity of
PZQ on S. haematobium, all of them only evaluated the
activity of racemic PZQ [18, 19, 29]. Studies on S. haema-
tobium are pivotal as many antischistosomals, oxamni-
quine, metrifonate and PZQ have very distinct profiles on
the different schistosome species [30]. To our knowledge,
our study is the first to investigate the activity of both en-
antiomers of PZQ, at three different doses, compared to a
single dose of PZQ, in vivo. Additionally, the activity of
both enantiomers was compared also to the main human
metabolite, trans-4-OH-PZQ, and the racemic drug,
in vitro. Our results show that R-PZQ is driving the anti-
schistosomal activity of PZQ, both in vitro and in vivo.
The IC50 value of racemic PZQ was 4.3× higher compared
to the enantiopure R-PZQ in vitro. In vivo results followed
a similar pattern: R-PZQ at 125 mg/kg resulted in WBRs
above 98%, as did a twice higher dose of PZQ, 250 mg/kg.
The latter result is in the line with findings from the dose-trans-4-OH-PZQ against adult worms of S. haematobium
l) r-value IC90 at 72 h (μg/ml) r-value Eudysmic ratio
0.965 0.09 0.978 501
0.940 0.03 0.940
0.923 5.98 0.923
0.891 3.31 0.891
Table 2 Worm burden reductions (WBRs) following different single oral doses of R, S-PZQ and PZQ
No. of hamsters
cured/treated
Mean no. of alive worms ± SD WBR
(%)
Female
WBR (%)
ED50
(mg/kg)Liver Mesenteric veins Total Females
Control 0/4 2.75 ± 3.8 31.0 ± 9.5 33.8 ± 16.8 15.3 ± 5.2 – – –
PZQ
250.0 mg/kg 3/4 0.25 ± 0.5 0 0.3 ± 0.5 0 99.3 100
200.0 mg/kgb 77.2 118.1
150.0 mg/kgb 66.1
100.0 mg/kgb 39.2
R-PZQ
125.0 mg/kg 2/4 0.25 ± 0.5 0.25 ± 0.5 0.5 ± 0.6 0 98.5 100 24.7a
62.5 mg/kg 1/4 5.0 ± 4.7 3.25 ± 3.6 8.3 ± 8.1 2.3 ± 3.3 75.6 85.2
31.0 mg/kg 0/3 6.7 ± 11.5 2.3 ± 2.3 9.0 ± 13.9 4.0 ± 6.9 73.3 73.8
S-PZQ
500.0 mg/kg 3/4 1.25 ± 2.5 0.75 ± 1.5 2.0 ± 4.0 0 94.1 100 127.6a 5.17c
250.0 mg/kg 2/4 4.0 ± 4.9 1.75 ± 2.1 5.8 ± 6.9 0 83.0 100
125.0 mg/kg 0/3 7.0 ± 6.2 11.0 ± 6.0 18.0 ± 12.1 0.7 ± 0.6 46.7 95.6
aDetermined on total worm burden reductions
bData reported by Webbe & James [18]
cEudysmic ratio
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infected hamsters conducted by Webbe & James, yielding
an ED50 of 118 mg/kg [18].
Strikingly, it seems that in case of S. haematobium in
contrast to S. mansoni [36], also S-PZQ possesses non-
negligible activity. An ED50 of 127.6 mg/kg was calcu-
lated for S-PZQ, which is close to the value of the
racemic drug. For comparison, S. mansoni-infected mice
treated with 800 mg/kg S-PZQ showed only a low WBR
of 19.6%. Hence, the eudysmic ratio is 64-fold lower for
S. haematobium compared to S. mansoni [36]. However,
it is worth highlighting that differences in the drug sen-
sitivity between the two species might also be due to dif-
ferences in the model, the hamster versus mouse model
[27]. Finally, also trans-4-OH-PZQ revealed a 2.3 and
2.4-fold higher activity (72 and 4 h, respectively) against
S. haematobium in vitro when compared to S. mansoni.
A contribution of S-PZQ and trans-4-OH-PZQ to PZQ’s
activity could explain the higher sensitivity to PZQ of
S. haematobium when compared to S. mansoni in
humans [30]. In humans, S. haematobium are residing
in the venus plexus of the bladder, getting exposed
mostly to high concentrations of S-PZQ and the metab-
olite, as a consequence of first pass metabolism. This is
in contrast to S. mansoni, where the adult worms are ex-
posed to un-metabolised drug in the mesenteric veins,
prior to reaching the liver.
In addition, we observed increased sensitivity of female
worms compared to the males in vivo for all entities stud-
ies. For example, the lowest dose of S-PZQ achieved afemale WBR of 95.6%, while the males were only mildly af-
fected (total WBR of 46.7%). The higher activity of PZQ on
female worms has been reported previously [20].
As mentioned above, due to the difficulties maintain-
ing the S. haematobium life-cycle, our in vivo data are
based on a single experiment and the in vitro data on
duplicate experiments. While we feel our data are robust
and in line with standard procedures, in order to draw a
final conclusion, which PZQ enantiomer to recommend
for the therapy of S. haematobium infections, additional
experiments would be beneficial.Conclusion
To conclude, we observed that R-PZQ possesses the
highest activity among the PZQ enantiomers and main
human metabolite tested against S. haematobium.
Surprisingly, S-PZQ- showed a high activity in vivo.
Additionally, the main human metabolite displayed an
activity higher than S-PZQ in vitro. In the line with the
current efforts to develop a paediatric formulation, an
enantioselective R-PZQ formulation might bear some
risk; however, further laboratory studies as well as
clinical trials, including pharmacokinetic/pharmaco-
dynamics relationship studies, would be required to con-
firm our findings.Abbreviations
ED50: Dose of the drug needed to reduce the worm burden by 50%;
IC50: Concentration of the drug, needed to kill 50% of the parasites;
PZQ: Praziquantel; WBR: Worm burden reduction
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